How Aging Reshapes the Mammalian Body: Atlas of 7 Million Cells Reveals All
Researchers at The Rockefeller University have created the most comprehensive single‑cell atlas of aging, profiling nearly 7 million cells from 21 mouse organs at 1, 5 and 21 months. The study identified over 1,800 cell subtypes, revealing that about a quarter of cell types change in abundance with age, with muscle and kidney cells declining and immune cells expanding. Crucially, many molecular and cellular alterations were synchronized across distant organs and showed pronounced sex differences, with 40% of changes differing between males and females. The authors highlight shared genomic regulatory hotspots and circulating cytokine signals as potential druggable targets to slow systemic aging.
AI-Powered Biochip Detects Genetic Markers in 20 Minutes
Scientists at Nanyang Technological University have unveiled an AI‑powered nanophotonic biochip that detects multiple microRNA biomarkers in about 20 minutes, eliminating the need for PCR amplification. The platform uses a light‑trapping nanocavity to boost fluorescent signals and a Mask R‑CNN model...
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
Johnson & Johnson’s hematology division secured FDA approval for a new multiple myeloma regimen—Tecvayli plus Darzalex Faspro—through the FDA Commissioner’s National Priority Voucher pilot. The approval came just 55 days after filing, marking the first blood‑cancer therapy to use the voucher...
Maneesh Goyal on Unlocking Clinical Data for Global Discovery — Mayo Clinic Platform | VIVE 2026
Mayo Clinic Platform, led by COO Maneesh Goyal, is building a global network that pools de‑identified, longitudinal clinical data to power AI‑driven discovery. The initiative already runs more than 300 predictive algorithms that can flag disease before symptoms emerge, shifting...
Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is...
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
This week’s biotech financing spotlighted platform‑driven innovation in oncology and immunology. Adcendo closed a $75 million Series C to expand its ADC pipeline, while Beeline Medicines launched with $300 million Series A to develop precision autoimmune therapies. Harbinger Health secured $100 million for its multi‑cancer...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
Atelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle East
Atelerix, a UK biotech, has signed a strategic partnership with Saudi Arabia’s JH Health Ltd, granting JH Health exclusive rights to distribute Atelerix’s non‑cryogenic hydrogel cell‑preservation solutions across the Middle East. The deal includes funding for high‑volume local manufacturing, regulatory...
Cellular Senescence and Mitochondrial Dysfunction and the Aging of the Vascular Endothelium
The review links cellular senescence and mitochondrial dysfunction to the aging of the vascular endothelium, showing how reduced nitric‑oxide, oxidative stress, and chronic inflammation drive atherosclerosis, hypertension, and blood‑brain barrier leakage. It details a feedback loop where mitochondrial bioenergetic decline...
Homoharringtonine as a Senotherapeutic Drug
Researchers used a large‑scale drug‑repositioning screen to identify homoharringtonine (HHT), an FDA‑approved anti‑leukemic agent, as a potent senotherapeutic. In vitro, HHT selectively eliminated senescent pre‑adipocytes while sparing healthy cells. In male mice, HHT cleared senescent adipocytes, restored white‑adipose tissue function,...
How Are Regulatory Factors Impacting Biosimilars
The FDA issued draft guidance in March that would drop certain pharmacokinetic (PK) studies for biosimilars, aiming to lower development costs. At the same time, the Inflation Reduction Act (IRA) and most‑favored‑nation (MFN) pricing provisions are reshaping how manufacturers price...
Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell — Episode 251
In episode 251 of the Xtalks Life Science Podcast, Kevin Caldwell, CEO and co‑founder of Ossium Health, discusses the company’s pioneering off‑the‑shelf bone‑marrow therapy derived from deceased organ donors. The treatment aims to solve long‑standing clinical and logistical hurdles in...
Viewpoint: CRISPR and mRNA — Under Attack by Technology Skeptics — Poised to Save Millions of Children with Rare Diseases
Rare genetic diseases affect roughly 25 million Americans and generate about $400 billion in annual medical costs, yet fewer than five percent have FDA‑approved therapies. The scarcity of treatments stems from the economics of drug development for tiny patient pools. Recent breakthroughs...
Major Organoids Companies Plus Latest TechBio News
The latest TechBio briefing spotlights the fastest‑growing private organoid firms, highlighting recent Series A‑C rounds that collectively raised over $500 million. Leaders such as OrganoTech, CellSphere, and BioMimic are scaling production pipelines to meet demand from pharma, diagnostics, and personalized‑medicine partners. The...
Inflammation & Immune System - A Deep Dive Into Genetic Pathways for Actionable Insights
A detailed genetic analysis of inflammation and immune pathways identified three high‑impact homozygous variants: PTPN22 R620W, CFH Y402H, and NFE2L2 –617. The report translates these findings into concrete clinical actions, including autoimmune and thyroid screening, baseline retinal imaging for age‑related...
